EC Number   |
Application |
Reference |
|---|
    3.5.1.2 | analysis |
construction of a L-glutaminase enzyme reactor based on immobilization of enzyme onto bamboo sticks through a glutaraldehyde modification to achieve covalent bonding. L-glutaminase-bamboo exhibits improved enzymatic hydrolysis performances, including high hydrolysis efficiency, prolonged stability (14 days) and good reusability and can efficiently be uesd for inhibitor screening |
755571 |
| 3.5.1.2 | food industry |
microbial glutaminases are enzymes with emerging potential in both the food and the pharmaceutical industries, potential application for bioconversion of glutamine to flavor-enhancing glutamic acid |
-, 720975 |
| 3.5.1.2 | food industry |
the enzyme is used in soy sauce fermentation |
-, 733562 |
| 3.5.1.2 | medicine |
acivicin along with Escherichia coli glutaminase synergistically reduces in vitro proliferation and matrigel invasion of human MCF-7 and OAW-42 cells. Combination of acivicin with glutaminase may provide a better therapeutic option than either of them separately for treating human breast and ovarian cancer |
687065 |
| 3.5.1.2 | medicine |
depresses some pro-inflammatory factors that occur during prolonged, exhaustive exercise |
656204 |
| 3.5.1.2 | medicine |
enzyme therapy at the dose of 10 unit/mouse in ascites tumor bearing mice, elicits a reduction in tumor growth. At day 5, 10 and 15 it is reduced by 60%, 95% and 89% respectively. The life span of the enzyme treated mice increases significantly with respect to control mice |
209035 |
| 3.5.1.2 | medicine |
purified L-glutaminase has a high toxic effect on Hela and Hep G2 cell lines with an IC50 value 18 and 12 microg/ml, respectively, and a moderate cytotoxic effect on HCT-116 and MCF7 cells, with an IC50 value 44 and 58 microg/ml, respectively |
754315 |
| 3.5.1.2 | medicine |
strategy to overcome acquired erlotinib resistance in NSCLC by inhibiting glutaminase activity. Compound 968, an inhibitor of the glutaminase C, when combined with erlotinib potently inhibits the cell proliferation of erlotinib-resistant NSCLC cells HCC827ER and NCI-H1975. The combination of compound 968 and erlotinib decreases glutaminase C and EGFR protein expression and inhibits glutaminase C activity in HCC827ER cells. Compound 968 combined with erlotinib down-regulates the glutamine and glycolysis metabolism in erlotinib-resistant cells |
754954 |
| 3.5.1.2 | more |
food-processing industry, increases the amount of the savory flavoring L-glutamic acid |
-, 654091 |
| 3.5.1.2 | more |
production of enzymically hydrolyzed plant proteins to reach high glutamic acid yields |
655373 |
